Biotechnology News and Research

RSS

SDI to discover biomarkers in collaboration with Fred Hutchinson Cancer Research Center

SDI (Strategic Diagnostics Inc.), a provider of biotechnology-based products and services, and Fred Hutchinson Cancer Research Center (the Hutchinson Center) today jointly announced they will collaborate to discover biomarkers for use in the early detection of a variety of cancers.

7 Jan 2010

MabCure signs clinical research agreement to diagnose ovarian cancer

MabCure, N.V. (“MabCure”) a wholly-owned subsidiary of MabCure Inc., a biotech company that has developed a series of highly specific monoclonal antibodies (MAbs) to combat various types of cancers, has signed a clinical research agreement with the Ramathibodi Hospital, Mahidol University in Bangkok, Thailand.

7 Jan 2010

BioMimetic Therapeutics amends and restates its agreement with Novartis Vaccines and Diagnostics

BioMimetic Therapeutics, Inc. today announced that effective December 31, 2009, the Company amended and restated its manufacturing and supply agreement with Novartis Vaccines and Diagnostics, Inc. for the supply of bulk rhPDGF-BB to BioMimetic.

6 Jan 2010

Bio-Rad Laboratories acquires Biotest AG's diagnostics businesses

Bio-Rad Laboratories, Inc., a multinational manufacturer and distributor of life science research and clinical diagnostics products, announced today that it has completed the purchase of certain diagnostics businesses of Biotest AG, including its diagnostics products in the areas of blood transfusion testing, transplantation, and infectious diseases for 45 million euros.

6 Jan 2010

Agilent Technologies, Covaris sign co-marketing agreement to streamline next-generation sequencing experiments

Agilent Technologies, Inc. (NYSE:A) and Covaris Inc. today announced a co-marketing agreement in which Covaris S2 DNA shearing technology will be marketed with the Agilent SureSelect Target Enrichment System to streamline next-generation sequencing experiments.

6 Jan 2010

Innexus Biotechnology designs new psoriasis product

InNexus Biotechnology Inc. (TSX.V: IXS) (www.ixsbio.com), a drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, today announced the development of a new psoriasis product based on its proprietary dermal permeating Transmab™ technology.

6 Jan 2010

Pharsight releases Phoenix NLME and Phoenix Connect

Pharsight, a market-leading provider of software and scientific services to improve productivity and decision-making in clinical drug development, today announced that it has released two new data analysis tools; Phoenix NLME and Phoenix Connect.

6 Jan 2010

Article about Enox Biopharma's self-sterilizing technology for catheters accepted for publication

A prestigious peer-review journal will publish an article in its January 2010 edition outlining a Vancouver BC based biomedical technology company's solution to the growing problem of hospital patients acquiring bacterial infections. The article about Enox Biopharma's self-sterilizing technology for catheters (patent pending) was accepted for publication in Antimicrobial Agents and Chemotherapy, a journal of the American Society for Microbiology and one of the most prominent publications in the field.

6 Jan 2010

Microfluidics introduces "Voice of the Customer" program

Microfluidics today introduced the "Voice of the Customer" program as part of its ongoing mission to improve communication and understanding between the company and its customers.

6 Jan 2010

Excaliard Pharmaceuticals initiates Phase 2 trials of EXC 001

Excaliard Pharmaceuticals, Inc. announced today the initiation of three proof of concept Phase 2 trials of EXC 001, an antisense medicine that reduces fibrosis, for the amelioration of skin scarring and other fibrotic disorders.

6 Jan 2010

Biotime ships six ACTCellerate progenitor cell lines to Millipore

BioTime, Inc. announced today that it has initiated shipments of stem cell research products to its worldwide distributor, Millipore Corporation, according to the terms of the co-marketing agreement between the two companies that was announced on July 9, 2009. BioTime has shipped inventory of six ACTCellerate™ progenitor cell lines to Millipore and plans to begin shipments of additional cell lines and ESpan™ cell growth media in the next several weeks.

6 Jan 2010

Bioheart signs distribution agreements to market Home Heart Failure Monitoring Systems in U.S.

Bioheart, Inc. announced today that the company has signed distribution agreements with Restoration Medical, McRay Medical, Alamo Scientific and Morey Medical. These distributors will assist Bioheart with introducing its Home Heart Failure Monitoring Systems to physicians and hospitals throughout the United States.

6 Jan 2010

Cancer Research UK and CRT to undertake phase I clinical trial of DI-B4

CANCER RESEARCH UK and Cancer Research Technology (CRT), the charity's development and commercialisation arm, are to undertake a phase I clinical trial of an investigational monoclonal antibody1 drug from Merck KGaA, Darmstadt, Germany, called DI-B4 - it is announced today (Monday).

6 Jan 2010

BioVectra signs agreements with Sandoz to commercialize and market Docetaxel

BioVectra Inc. announced today it has signed agreements with Sandoz Inc. of Princeton, New Jersey, for Sandoz to commercialize and market the Abbreviated New Drug Application (ANDA) for Docetaxel for injection, the generic version of Taxotere®, developed by BioVectra.

6 Jan 2010

Laureate Pharma, Selexis SA collaborate to provide streamlined access to complementary contract services

Laureate Pharma, Inc. a US based biopharmaceutical contract manufacturing organization and Selexis SA, a Swiss based contract developer of high performance production cell lines, jointly announced today their continued collaboration via a joint-marketing relationship. This expanded relationship provides streamlined access to a set of highly complementary contract services.

6 Jan 2010

WPI researchers lay groundwork for new generation of advanced prosthetic limbs

The conflicts in Iraq and Afghanistan have left a terrible legacy: more than 1,200 returning American soldiers have lost one or more limbs. To address this growing national need, researchers at Worcester Polytechnic Institute (WPI) are laying the groundwork for a new generation of advanced prosthetic limbs that will be fully integrated with the body and nervous system.

5 Jan 2010

Bioject Medical Technologies collaborates with MPI Research to explore drug and device opportunities

Bioject Medical Technologies Inc. (OTCBB:BJCT), a leading developer of needle-free injection therapy systems, today announced that it has established a strategic alliance with MPI Research, a leading pre-clinical research organization with experience in the development of injectable therapeutics.

5 Jan 2010

Phase 2 study evaluating VBL Therapeutics' lead compound VB-201 initiated

VBL Therapeutics today announced the initiation of a Phase 2 efficacy and safety study evaluating lead compound VB-201 for the treatment of patients with psoriasis. VB-201 is poised to be a first-in-class, orally-administered immune response modifier expected to reduce inflammation in a broad range of conditions such as psoriasis.

5 Jan 2010

Dow AgroSciences to receive global license to develop and commercialize COT102 transgenic event

Syngenta and Dow AgroSciences, a wholly owned subsidiary of The Dow Chemical Company (NYSE: DOW), announced today that Syngenta has granted Dow AgroSciences licenses to a number of VipCot(TM) cotton varieties, as well as access to its COT102 cotton transgenic event.

5 Jan 2010

BioPlex 2200 Anti-CCP test for early detection of RA launched

Bio-Rad Laboratories, Inc., a multinational manufacturer and distributor of life science research and clinical diagnostics products, and Axis-Shield plc, an international in-vitro diagnostics (IVD) company, today announced the launch of Bio-Rad's BioPlex® 2200 Anti-CCP test for the early detection of rheumatoid arthritis.

5 Jan 2010

Biotechnology News and Research

SDI to discover biomarkers in collaboration with Fred Hutchinson Cancer Research Center

MabCure signs clinical research agreement to diagnose ovarian cancer

BioMimetic Therapeutics amends and restates its agreement with Novartis Vaccines and Diagnostics

Bio-Rad Laboratories acquires Biotest AG's diagnostics businesses

Agilent Technologies, Covaris sign co-marketing agreement to streamline next-generation sequencing experiments

Innexus Biotechnology designs new psoriasis product

Pharsight releases Phoenix NLME and Phoenix Connect

Article about Enox Biopharma's self-sterilizing technology for catheters accepted for publication

Microfluidics introduces "Voice of the Customer" program

Excaliard Pharmaceuticals initiates Phase 2 trials of EXC 001

Biotime ships six ACTCellerate progenitor cell lines to Millipore

Bioheart signs distribution agreements to market Home Heart Failure Monitoring Systems in U.S.

Cancer Research UK and CRT to undertake phase I clinical trial of DI-B4

BioVectra signs agreements with Sandoz to commercialize and market Docetaxel

Laureate Pharma, Selexis SA collaborate to provide streamlined access to complementary contract services

WPI researchers lay groundwork for new generation of advanced prosthetic limbs

Bioject Medical Technologies collaborates with MPI Research to explore drug and device opportunities

Phase 2 study evaluating VBL Therapeutics' lead compound VB-201 initiated

Dow AgroSciences to receive global license to develop and commercialize COT102 transgenic event

BioPlex 2200 Anti-CCP test for early detection of RA launched

Biotechnology eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News